Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Polomar Health Services, Inc. (PMHS)
Los Angeles, CA, US
Polomar Health Services, Inc. operates as a retail compounding pharmacy. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded with vitamin B-12 and/or metformin; and intends to launch PoloMeds for diabetes medications, including metformin compounds, sulfonylureas, and insulin, as well as compounded erectile dysfunction medications inhalable sildenafil. It also includes dermatological formulations for the treatment of acne, alopecia areata, basal cell carcinoma, Becker’s nevus, vitiligo, and other common skin conditions. In addition, it provides prescription fulfillment services for third party web based tele-health platforms. The company is based in Los Angeles, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -52.00% | -52.00% | -40.00% | -55.00% | -10.00% | -91.00% | -81.54% | -97.98% | -99.98% | -96.40% | -99.89% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+1,002.0% ★ Q4'25: +1,190.6% (vs Q4'24)
-
EPS growth Medical - Care Facilities: +19.2%-680.0% Q4'25: -737.6% (vs Q4'24)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%-1,588.8% Q4'25: +30.1% (vs Q4'24)
-
EBIT margin Medical - Care Facilities: +11.3%-1,627.6% Q4'25: -1,414.9% (vs Q4'24)
-
ROIC Medical - Care Facilities: +6.8%— Q4'25: +2,670.2% (vs Q4'24)
-
Share dilution Medical - Care Facilities: +0.0%+0.4% Q4'25: +0.4% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×0.00× Q4'25: 0.00× (vs Q4'24)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-15 | TIERNEY TERRENCE MCGILL | Director / Officer | A-Award | A | Common Stock | 7,695 | 2,693.00 | 20.72M | 141,028 | D | ↗ |
| 2025-07-15 | TIERNEY TERRENCE MCGILL | Director / Officer | A-Award | A | Common Stock | 8,333 | 2,917.00 | 24.31M | 133,333 | D | ↗ |
| 2025-06-27 | TIERNEY TERRENCE MCGILL | Director / Officer | A-Award | A | Common Stock | 125,000 | 43,750.00 | 5.47B | 125,000 | D | ↗ |
| 2024-10-01 | Spiegel David A. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-30 | Gordon Daniel Later | 10% Owner | — | — | Common Stock, par value $0.001 | 0 | 0.00 | — | 10,370,707 | D | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Terrence Tierney | President, CEO, Secretary & Director | 161.8K | male |
| Charlie Lin | CFO, Controller & Treasurer | 130.0K | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PMHS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
